New treatments for pancreatic cancer using protein inhibitors
Inhibitors of Oxidative Protein Folding For The Treatment of Cancer
This study is looking at new treatments for pancreatic cancer that could work better when combined with current therapies, aiming to find more effective options for patients facing this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-10877069 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for pancreatic ductal adenocarcinoma (PDAC), a highly lethal form of cancer. The team is investigating a new class of protein disulfide isomerase (PDI) inhibitors that have shown promise in enhancing the effectiveness of existing cancer treatments, particularly histone deacetylase (HDAC) inhibitors. By exploring the molecular mechanisms behind this synergy and testing these inhibitors in preclinical models, the research aims to identify more effective treatment options for patients with PDAC and other difficult-to-treat cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma or other solid tumors that may benefit from novel therapeutic approaches.
Not a fit: Patients with early-stage pancreatic cancer or those whose cancer is not responsive to current treatment modalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients suffering from pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous studies have shown promise with similar approaches targeting protein folding mechanisms in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Dolloff, Nathan G. — Medical University of South Carolina
- Study coordinator: Dolloff, Nathan G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.